30 AugStarting the potential for a new class of cancer drugs targeting metabolic enzymes.

Finally, Agios researcher Valeria Fantin, Ph.D., gave an oral presentation Cancer-linked mutations in IDH1 and IDH2 produce 2HG,on Monday , April 19, discussing the results of the research, which were the basis of a Character publication in November 2009.. Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel medicines in neuro-scientific cancer metabolism, today announced multiple presentations in the American Association for Tumor Analysis 101st Annual Meeting that highlight cancer metabolism as a procedure for identify new methods to treat cancer, starting the potential for a new class of cancer drugs targeting metabolic enzymes.NPR: Says’ Abortion Legislation Questioned By Critics Condition legislatures are considering a new wave of abortion restrictions this season. Some require longer waiting periods to get abortions. Others would direct doctors to show women ultrasounds of fetuses. But critics say brand-new conservative lawmakers are pushing these bills to check the limits . This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health Information, an editorially independent news service, is a scheduled system of the Kaiser Family Foundation, a nonpartisan health care policy research company unaffiliated with Kaiser Permanente.

A practical instruction to the management of epilepsy Approaches to treating epilepsy are being increasingly refined seeing that more is understood about the various syndromes and their response to medicines.